CytomX (CTMX) Gains in Active Trading for June 22

Equities Staff  |

CytomX Therapeutics Inc (NASDAQ:CTMX) shares gained 5.26% today on 1,226,901 shares - in comparison to their 30 day average of 795,191 shares traded.

After today’s close at $1.80 the company has a 50 day moving average of $1.69.

The company expects its next earnings on 2022-08-04.

CytomX lost 60.51% so far this year.

For technical charts, analysis, and more on CytomX visit the company profile.

About CytomX Therapeutics Inc

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics, based on its Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.

To get more information on CytomX Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: CytomX Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Will Mining Stocks Fall Further?
3 Reasons To Be Optimistic About the Global Shipping Industry
The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks

Market Movers

Sponsored Financial Content